Antimicrobial Activity of Dioxidine and Dioxidine-Containing Medicine «nosolin-Ultra, Nasal Drops»

The overuse and inappropriate use of systemic antibiotics is the most serious cause of problems associated with the increasing resistance of bacterial pathogens. What served as the basis for WHO to call the XXI century “The era of antibiotic resistance”. The wide spread of resistant strains of microorganisms, the growth of severe and complicated forms of diseases leads to an increase in the frequency of unfavorable treatment outcomes. In the Russian Federation, an increase in the incidence of acute rhinosinusitis from 4.6 to 12.7 cases per 1000 population has been noted in the last decade. The incidence of acute rhinosinusitis in Europe is recorded in 6.4 ± 3.6 of all cases of visits to primary care physicians. Up to 38% of outpatients in the ENT profile suffer from various forms of otitis media, including up to 30% of acute otitis media. The most important way to overcome the global problem of antibiotic resistance, along with the delayed use of systemic antibacterial drugs initiated by the world medical community, is to switch to the active use of topical drugs with antimicrobial activity. The article provides an overview of the data of domestic and foreign literature on the properties of a topical antibacterial drug with the active ingredient hydroxymethylquinoxaline dioxide. The results of experimental work and clinical studies, proving the high efficacy and safety of the drug in the complex treatment of bacterial infections of the upper respiratory tract, have been analyzed.

show abstract

Possibilities of tropical treatment of bacterial ENT infections

Шамкина

Krivopalov

Panchenko

et al. 2021

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

Topical antibiotic therapy for perforated otitis in the COVID-19 pandemic

et al. 2022

View full text Add to dashboard Cite

The developing resistance of microorganisms to the effects of antibacterial drugs creates difficulties in the treatment of purulent diseases. This is especially reasonable in the pandemic of a new coronavirus infection (COVID-19). The aggressive effect of new strains of the virus on the mucous membrane of the nasal cavity and nasopharynx contributes to the occurrence of complications such as acute purulent otitis media and exacerbation of chronic purulent otitis, both during coronavirus infection and in the postcovid period. Even before the start of the pandemic, antibiotic resistance was already one of the big problems in most countries of the world, this was due to the frequent unjustified appointment of systemic antibacterial agents for viral infection, as well as uncontrolled self-medication of the population with all available drugs. Due to the fear of people getting sick with COVID-19 and disagreements among doctors in treatment tactics, the use of systemic antibiotics and hormonal drugs increased already in the first months of the pandemic. In the future, the unjustifiability of this tactic was proved, but many doctors continued to prescribe several systemic antibacterial drugs to patients with uncomplicated viral infection. Under the current conditions, when there is evidence of bacterial infection, it is rational to use local antibacterial drugs, which allows you to quickly reach high concentrations in the focus of inflammation and avoid side effects of systemic antibiotics. Among the existing means in the complex therapy of perforated otitis, a special place belongs to the preparations of the group of quinoxaline derivatives, which include hydroxymethylquinoxalindioxide (Dioxidine). The advantage of the drug is its effectiveness against resistant microorganisms, as well as stimulation of marginal tissue regeneration. This property is especially important in the treatment of perforated otitis media.

show abstract

Hydroxymethylquinoxalindioxide as levarage points for otorhinolaryngology

Eremeeva,

Nagovskaya,

Morozova

2023

Medicinskij sovet

View full text Add to dashboard Cite

Hydroxymethylquinoxaline dioxide, better known as Dioxydin®, holds a special place among topical antimicrobials. The drug has the proven bactericidal action against a wide spectrum of aerobic and anaerobic bacteria, showed good results in otorhinolaryngology as a topical drug to treat bacterial diseases of upper respiratory tract and ear. The authors performed the search for publications among the sources of electronic libraries, such as National Electronic Library (NEB), eLIBRARY, Cyberleninka, Rucont, as well as electronic search engines Pubmed and Google Scholar for the period from 2015 to 2022. The literature analysis resulted in 9 domestic studies, including 6 prospective comparative (4 randomized) studies, two prospective non-comparative studies, and one retrospective descriptive study. The prospective studies involved 400 patients, and the retrospective study analysed the administration in 150 patients. In these studies, hydroxymethylquinoxaline dioxide (Dioxydin®) was used to treat culture-proven infections of upper respiratory tract and ear, both acute and exacerbations of chronic ones. In addition to 0.5% and 1% solutions, which are widely used in ENT practice and need to be prediluted, two new formulations of the drug, fully ready for use, also draws attention: Dioxydin® 2.5 mg/ml, ear drops, and Dioxydin® 0.25 mg/ml, sore throat gargle for topical use. A retrospective review of papers on the use of hydroxymethylquinoxaline dioxide (Dioxydin®) for the topical treatment of upper respiratory tract and ear diseases caused by bacterial agents shows high efficacy, safety and low risk of resistance development. It is promising to conduct studies demonstrating additional therapeutic activity of the Dioxydin®.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Antimicrobial Activity of Dioxidine and Dioxidine-Containing Medicine «nosolin-Ultra, Nasal Drops»

Cited by 4 publications

References 9 publications

Possibilities of tropical treatment of bacterial ENT infections

Possibilities of tropical treatment of bacterial ENT infections

Topical antibiotic therapy for perforated otitis in the COVID-19 pandemic

Hydroxymethylquinoxalindioxide as levarage points for otorhinolaryngology

Contact Info

Product

Resources

About